Genmab CEO says Janssen should "show respect" as royalty strife nears conclusion

Danish biotech company Genmab and Johnson & Johnson’s pharmaceutical arm Janssen have been fighting it out over royalty payments for a year. As the verdict draws near, Genmab CEO Jan van de Winkel has taken a jab at Janssen, saying it ought to show Genmab some respect.

Jan van de Winkel, CEO of Genmab | Photo: PR / Genmab

For around a year, Genmab and its US-based partner Janssen, the pharmaceutical arm of Johnson & Johnson, have been in a legal battle concerning royalty payments from the latter to the Danish biotech company, Danish business daily Børsen reports.

A ruling in the arbitration case is soon expected to come in, but in the run-up to the decision, CEO of Genmab Jan van de Winkel has demanded respect from his partner company.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs